CN101484185A - 治疗用肽体的冻干制剂 - Google Patents

治疗用肽体的冻干制剂 Download PDF

Info

Publication number
CN101484185A
CN101484185A CNA200780022610XA CN200780022610A CN101484185A CN 101484185 A CN101484185 A CN 101484185A CN A200780022610X A CNA200780022610X A CN A200780022610XA CN 200780022610 A CN200780022610 A CN 200780022610A CN 101484185 A CN101484185 A CN 101484185A
Authority
CN
China
Prior art keywords
composition
sucrose
weight
mannitol
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200780022610XA
Other languages
English (en)
Chinese (zh)
Inventor
W·J·卡拉汉
R·L·小雷梅尔
G·拉特纳斯沃米
R·F·拉蒂波夫
D·刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38625630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101484185(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to CN201711043851.4A priority Critical patent/CN107789325A/zh
Publication of CN101484185A publication Critical patent/CN101484185A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
CNA200780022610XA 2006-04-21 2007-04-20 治疗用肽体的冻干制剂 Pending CN101484185A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711043851.4A CN107789325A (zh) 2006-04-21 2007-04-20 治疗用肽体的冻干制剂

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79399706P 2006-04-21 2006-04-21
US60/793,997 2006-04-21
US11/788,697 US9283260B2 (en) 2006-04-21 2007-04-19 Lyophilized therapeutic peptibody formulations
US11/788,697 2007-04-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201711043851.4A Division CN107789325A (zh) 2006-04-21 2007-04-20 治疗用肽体的冻干制剂

Publications (1)

Publication Number Publication Date
CN101484185A true CN101484185A (zh) 2009-07-15

Family

ID=38625630

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA200780022610XA Pending CN101484185A (zh) 2006-04-21 2007-04-20 治疗用肽体的冻干制剂
CN201711043851.4A Pending CN107789325A (zh) 2006-04-21 2007-04-20 治疗用肽体的冻干制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201711043851.4A Pending CN107789325A (zh) 2006-04-21 2007-04-20 治疗用肽体的冻干制剂

Country Status (38)

Country Link
US (2) US9283260B2 (enExample)
EP (6) EP2594286A1 (enExample)
JP (6) JP5432705B2 (enExample)
KR (2) KR101236042B1 (enExample)
CN (2) CN101484185A (enExample)
AR (1) AR060617A1 (enExample)
AU (1) AU2007240656A1 (enExample)
BR (1) BRPI0710508B8 (enExample)
CA (1) CA2649292C (enExample)
CR (3) CR20170130A (enExample)
CY (1) CY1118038T1 (enExample)
DK (1) DK2018183T3 (enExample)
EA (2) EA017085B1 (enExample)
ES (1) ES2599318T3 (enExample)
GE (1) GEP20156253B (enExample)
HR (1) HRP20161653T1 (enExample)
HU (1) HUE032144T2 (enExample)
IL (3) IL194653A (enExample)
JO (1) JO3324B1 (enExample)
LT (1) LT2018183T (enExample)
MA (1) MA30474B1 (enExample)
MX (1) MX2008013393A (enExample)
MY (1) MY162816A (enExample)
NO (1) NO344947B1 (enExample)
NZ (1) NZ596367A (enExample)
PE (1) PE20081196A1 (enExample)
PH (1) PH12014502880A1 (enExample)
PL (1) PL2018183T3 (enExample)
PT (1) PT2018183T (enExample)
RS (1) RS55428B1 (enExample)
SG (2) SG182887A1 (enExample)
SI (1) SI2018183T1 (enExample)
TN (1) TNSN08391A1 (enExample)
TW (1) TWI352598B (enExample)
UA (2) UA116080C2 (enExample)
UY (1) UY30302A1 (enExample)
WO (1) WO2007124090A2 (enExample)
ZA (1) ZA200808485B (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102586217A (zh) * 2011-12-16 2012-07-18 深圳市海普瑞药业股份有限公司 肝素黄杆菌肝素酶ⅰ、ⅱ、ⅲ的冻干保存方法
CN104274827A (zh) * 2013-07-01 2015-01-14 上海贺普药业股份有限公司 贺普拉肽的制剂
CN110448677A (zh) * 2012-08-15 2019-11-15 克里登蒂斯股份公司 用于制备治疗牙齿损伤的组合物的方法
CN112203698A (zh) * 2018-03-26 2021-01-08 通用电气医疗集团股份有限公司 制剂及制备方法
CN113171447A (zh) * 2014-08-20 2021-07-27 博尔托拉制药公司 Xa因子解毒剂的冻干制剂
CN117186173A (zh) * 2023-09-14 2023-12-08 海南大学 抑制Aβ42聚集并降低其细胞毒作用的三肽化合物

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1783222T3 (da) 1998-10-23 2012-07-09 Kirin Amgen Inc Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
DK2130554T3 (da) 1999-02-22 2012-12-03 Univ Connecticut Albuminfrie faktor VIII-præparater
JP4817503B2 (ja) 1999-06-01 2011-11-16 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
EE200300509A (et) 2001-04-13 2004-08-16 Biogen, Inc. Antikehad VLA-1 vastu
WO2007093042A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US7704977B2 (en) 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
AU2011265555B2 (en) * 2006-04-21 2016-03-10 Amgen Inc. Lyophilized therapeutic peptibody formulations
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
CN105381459A (zh) 2006-05-25 2016-03-09 比奥根Ma公司 治疗中风的方法
JP5671451B2 (ja) * 2008-05-07 2015-02-18 メリオン・リサーチ・Ｉｉｉ・リミテッド ＧｎＲＨ関連化合物の組成物および調製プロセス
KR101752508B1 (ko) * 2008-11-07 2017-06-29 백스터 인터내셔널 인코포레이티드 제8 인자 제형
US20120183546A1 (en) 2009-09-23 2012-07-19 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
ES2700925T3 (es) * 2010-01-19 2019-02-20 Hanmi Science Co Ltd Formulaciones líquidas para conjugado de eritropoyetina de acción prolongada
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
EA201390810A1 (ru) 2010-12-02 2013-09-30 Онколитикс Байотек Инк. Жидкие вирусные составы
WO2012075376A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
JP5759211B2 (ja) * 2011-03-11 2015-08-05 三洋化成工業株式会社 凍結乾燥方法
CA2840212A1 (en) 2011-06-29 2013-01-03 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
DE102011055889B4 (de) * 2011-11-30 2013-08-01 Otc Gmbh Verfahren zur Herstellung eines Protein-Hydrolysates
RU2482128C1 (ru) * 2011-12-28 2013-05-20 Замертон Холдингс Лимитед Пептиды, обладающие цитопротекторной активностью
US10316095B2 (en) * 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
EP2644186A1 (en) 2012-03-26 2013-10-02 OTC GmbH Hair conditioning composition for permanent and semi-permanent hair coloration applications
KR20150034170A (ko) * 2012-06-25 2015-04-02 이머전트 프로덕트 디벨롭먼트 게이더스버그 인코포레이티드 온도 안정성 백신 제형
CA2928851A1 (en) 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
AU2014228423A1 (en) * 2013-03-15 2015-11-05 Amgen Inc. Myostatin antagonism in human subjects
WO2015035405A1 (en) * 2013-09-09 2015-03-12 Pinta Biotherapeutics, Inc. Myostatin antagonist for treatment of pew in esrd patients
TR201902755T4 (tr) * 2013-11-07 2019-03-21 Dr August Wolff Gmbh & Co Kg Arzneimittel Depolama kararliliğina sahi̇p li̇yofi̇li̇ze tri̇pepti̇t formülasyonlari.
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CA2932798C (en) * 2013-12-06 2022-09-20 The Broad Institute, Inc. Formulations for neoplasia vaccines
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
WO2015100344A1 (en) 2013-12-27 2015-07-02 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
CA2943919A1 (en) * 2014-03-29 2015-10-08 Intas Pharmaceuticals Ltd. Lyophilized pharmaceutical composition of fc-peptide fusion protein
EP3757134B1 (en) * 2014-05-28 2024-03-06 NoNO Inc. Chloride salt of tat-nr2b9c
EP3155008B1 (en) * 2014-06-13 2020-08-26 Atara Biotherapeutics, Inc. Formulated receptor polypeptides and related methods
JP6671141B2 (ja) * 2014-10-21 2020-03-25 大日本住友製薬株式会社 懸濁液剤
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
ES3049406T3 (en) 2014-12-19 2025-12-16 Broad Inst Inc Methods for profiling the t-cell-receptor repertoire
CN107205948B (zh) 2015-01-29 2021-12-14 诺和诺德股份有限公司 包含glp-1激动剂和肠溶衣的片剂
US10857229B2 (en) 2015-04-30 2020-12-08 Amgen Inc. Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane
CN108025048B (zh) 2015-05-20 2022-10-25 博德研究所 共有的新抗原
CN108601819B (zh) 2015-12-17 2022-03-15 约翰霍普金斯大学 用死亡受体激动剂改善系统性硬化症
US11389510B2 (en) 2016-01-08 2022-07-19 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
EP3400018A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with increased nep stability
PL3400019T3 (pl) 2016-01-08 2023-01-23 Ascendis Pharma Growth Disorders A/S Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy
JP6992262B2 (ja) * 2016-03-31 2022-02-15 東ソー株式会社 変性抗体測定試薬の製造方法
JP7281795B2 (ja) 2016-04-07 2023-05-26 ザ・ジョンズ・ホプキンス・ユニバーシティー 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
US10654922B2 (en) * 2016-05-13 2020-05-19 Askgene Pharma Inc. Angiopoietin 2, VEGF dual antagonists
IL308416B2 (en) 2016-12-02 2025-08-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
JP2017155046A (ja) * 2017-04-05 2017-09-07 イーストポンド・ラボラトリーズ・リミテッド シクロデキストリンを含有する細胞水和組成物
AU2018334502A1 (en) 2017-09-15 2020-03-12 Amgen Inc. Process for lyophilized pharmaceutical formulation of a therapeutic protein
US20200255496A1 (en) * 2017-09-18 2020-08-13 Amgen Inc. Vegfr-fc fusion protein formulations
CA3189025A1 (en) * 2017-12-22 2019-06-27 Samsung Bioepis Co., Ltd. Liquid composition comprising vegf antagonist
CN108159413B (zh) * 2018-01-10 2021-07-06 杭州洪桥中科基因技术有限公司 一种动物用冻干活疫苗及其制备方法
MA52630B1 (fr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Procédés de traitement de l'hémophilie a
US20210236636A1 (en) * 2018-07-31 2021-08-05 Amgen Inc. Pharmaceutical formulations of masked antibodies
KR102893903B1 (ko) 2019-02-11 2025-12-01 아센디스 파마 그로우쓰 디스오더스 에이/에스 Cnp 접합체의 건조 약학 제제
JP7266108B2 (ja) 2019-02-18 2023-04-27 イーライ リリー アンド カンパニー 治療用抗体製剤
CN113660953A (zh) * 2019-04-01 2021-11-16 豪夫迈·罗氏有限公司 用于稳定含蛋白质制剂的组合物和方法
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
EP3744319B1 (en) * 2019-05-28 2022-10-19 Ilkogen Ilac Sanayi Ve Ticaret A.S. A stable lyophilized formulation for hybrid fc fused g-csf
JP2019178154A (ja) * 2019-06-18 2019-10-17 イーストポンド・ラボラトリーズ・リミテッド シクロデキストリンを含有する細胞水和組成物
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
CN115427569A (zh) * 2019-12-02 2022-12-02 奥特万科学有限公司 下气道疾病的治疗
KR20220122648A (ko) * 2019-12-03 2022-09-02 차이나 메디칼 유니버시티 올리고펩티드, 이의 테스트 키트, 및 이의 의약 조성물
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
EP4314083A4 (en) * 2021-03-31 2025-04-09 Hangzhou Exegenesis Bio Ltd. Fusion molecules targeting VEGF and angiopoietin and uses thereof
KR20240109277A (ko) 2021-12-01 2024-07-10 유씨비 바이오파마 에스알엘 Fab-peg를 포함하는 제제
US20240076597A1 (en) * 2022-09-02 2024-03-07 Terumo Bct, Inc. Methods for cell expansion, differentiation, and/or harvesting of natural killer cells using hollow-fiber membranes
WO2024133908A1 (en) * 2022-12-23 2024-06-27 Syna Therapeutics, S.L. Stable pharmaceutical compositions comprising romiplostim
WO2024263570A1 (en) * 2023-06-23 2024-12-26 The Regents Of The University Of Michigan Nanoparticle compositions associated with peptides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004801A1 (en) * 1995-07-27 1997-02-13 Genentech, Inc. Stabile isotonic lyophilized protein formulation
WO2001083525A2 (en) * 2000-05-03 2001-11-08 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
WO2004092215A2 (en) * 2003-04-09 2004-10-28 Amgen Inc. Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
CN1596266A (zh) * 2001-10-11 2005-03-16 安姆根有限公司 人血管生成素－2的特异结合剂

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) * 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) * 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) * 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) * 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) * 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
DE3244265A1 (de) 1982-11-30 1984-05-30 Cassella Ag, 6000 Frankfurt Weichmacheremulsion, verfahren zu ihrer herstellung und ihre anwendung
US4503235A (en) 1983-03-11 1985-03-05 Warner-Lambert Company Process for producing 4-carbamoyl-1H-imidazolium-5-olate
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0315456B1 (en) 1987-11-05 1994-06-01 Hybritech Incorporated Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5089261A (en) * 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5362852A (en) * 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
NZ244778A (en) 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
DK0615451T3 (da) 1992-05-26 2006-04-24 Immunex Corp Hidtil ukendt cytokin der binder til CD30
DE69332485T2 (de) 1992-08-11 2003-11-13 The President And Fellows Of Harvard College, Cambridge Immunmodulierende peptide
GB9225448D0 (en) 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5880096A (en) * 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5786331A (en) * 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5608035A (en) * 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5844929A (en) * 1994-02-24 1998-12-01 British Telecommunications Public Limited Company Optical device with composite passive and tapered active waveguide regions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU693478B2 (en) 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity
IL116026A (en) 1994-11-22 2005-08-31 Rhone Poulenc Rorer Sa Peptides capable of linking to the sh3 domain of gap, nucleotide sequences encoding the same, their preparation and uses
US5888763A (en) 1994-12-30 1999-03-30 The Rockefeller University Peptides specific for the first Crk-SH3 domain
AU695129B2 (en) * 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
IL113159A0 (en) 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US5746516A (en) 1995-08-11 1998-05-05 Hitachi Powdered Metals Co., Ltd. Porous bearing system having internal grooves and electric motor provided with the same
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
JPH09151200A (ja) 1995-09-29 1997-06-10 Ajinomoto Co Inc ヒト胃癌に対する免疫応答を誘導できるペプチド及び該ペプチドを含むヒト胃癌治療、予防剤
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US5714577A (en) 1996-01-26 1998-02-03 University Of Pittsburgh Antimicrobial peptides
IL117223A0 (en) 1996-02-22 1996-06-18 Yeda Res & Dev Antipathogenic polypeptides and compositions comprising them
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU2597897A (en) 1996-03-28 1997-10-17 Brigham And Women's Hospital Peptide ligands of the urokinase receptor
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
FR2748028B1 (fr) 1996-04-30 1998-08-14 Lab Francais Du Fractionnement Peptides derives du facteur von willebrand et leur utilisation comme anticoagulant
EP0911393B1 (en) 1996-06-07 2007-01-10 Takeda Pharmaceutical Company Limited Peptide having cortistatin or somatostatin activity, process for the production of the same, and use of the same
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
JP2001501600A (ja) 1996-09-10 2001-02-06 ザ バーナム インスティテュート 腫瘍ホーミング分子、それに由来する結合体、およびその使用方法
JP2001501619A (ja) * 1996-10-04 2001-02-06 アムジェン インコーポレーテッド ｍｐｌリガンドを含有する医薬組成物
CA2267139A1 (en) 1996-10-08 1998-04-16 Ton Logtenberg Methods and means for selecting peptides and proteins having specific affinity for a target
WO1998033812A1 (en) 1997-02-05 1998-08-06 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
ES2284203T5 (es) 1997-04-16 2016-03-11 Amgen Inc. Proteínas de unión a osteoprotegerina y sus receptores
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
IL135835A0 (en) 1997-11-07 2001-05-20 Conjuchem Inc Novel conjugates of opioids and endogenous carriers
WO1999038526A1 (en) 1998-01-29 1999-08-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variant peptide ligands that selectively induce apoptosis
US6423685B1 (en) 1998-03-05 2002-07-23 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6235872B1 (en) 1998-03-12 2001-05-22 The Burnham Institute Proapoptotic peptides dependence polypeptides and methods of use
WO1999047151A1 (en) 1998-03-20 1999-09-23 Chugai Pharmaceutical Co., Ltd. Peptide ligands for the erythropoietin receptor
EP0947524A1 (en) 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
CA2327811A1 (en) 1998-04-06 1999-10-14 Advanced Immunit, Inc. Short peptides for treatment of neurological degenerative diseases
ATE399567T1 (de) * 1998-04-28 2008-07-15 Serono Lab Peg konjugate von lhrh analogen
EP0972780A1 (en) 1998-05-18 2000-01-19 Applied Research Systems ARS Holding N.V. Il-6 antagonist peptides
DE69938782D1 (de) 1998-05-22 2008-07-03 Abbott Lab Peptide als antiangiogene arzneimittel
US5932548A (en) 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
WO2000001402A1 (en) 1998-07-02 2000-01-13 Envision Biomedical Consulting Antiproliferative and antiviral proteins and peptides
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
US6906170B1 (en) 1998-08-21 2005-06-14 Yeda Research And Development Co. Ltd. Anti-inflammatory peptides derived from IL-2 and analogues thereof
MXPA01003790A (es) 1998-10-16 2002-09-18 Biogen Inc Proteinas de fusion beta - interferon y sus usos.
DK1783222T3 (da) * 1998-10-23 2012-07-09 Kirin Amgen Inc Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU2880400A (en) 1999-02-12 2000-08-29 Amgen, Inc. Tnf-related proteins
US6635646B1 (en) * 1999-05-04 2003-10-21 Schering Corporation Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US6853809B2 (en) 2001-01-30 2005-02-08 Koninklijke Philips Electronics N.V. Camera system for providing instant switching between wide angle and full resolution views of a subject
CN100448891C (zh) * 2001-05-11 2009-01-07 安姆根有限公司 与tall-1结合的肽和相关分子
RU2180233C1 (ru) 2001-06-26 2002-03-10 Общество с ограниченной ответственностью "Протеиновый контур" Способ получения жидких лекарственных форм рекомбинантных белков
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
WO2004019860A2 (en) 2002-08-28 2004-03-11 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
WO2004039337A2 (en) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
WO2004058988A2 (en) * 2002-12-20 2004-07-15 Amgen, Inc. Binding agents which inhibit myostatin
EP1773400A2 (en) 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
MX2007003320A (es) * 2004-09-24 2007-05-18 Amgen Inc Moleculas fc modificadas.
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP3035305B1 (en) 2014-12-18 2016-11-16 Axis AB Enclosure and arrangement for recess mounting of a camera or camera head

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004801A1 (en) * 1995-07-27 1997-02-13 Genentech, Inc. Stabile isotonic lyophilized protein formulation
WO2001083525A2 (en) * 2000-05-03 2001-11-08 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
CN1596266A (zh) * 2001-10-11 2005-03-16 安姆根有限公司 人血管生成素－2的特异结合剂
WO2004092215A2 (en) * 2003-04-09 2004-10-28 Amgen Inc. Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102586217A (zh) * 2011-12-16 2012-07-18 深圳市海普瑞药业股份有限公司 肝素黄杆菌肝素酶ⅰ、ⅱ、ⅲ的冻干保存方法
CN110448677A (zh) * 2012-08-15 2019-11-15 克里登蒂斯股份公司 用于制备治疗牙齿损伤的组合物的方法
CN104274827A (zh) * 2013-07-01 2015-01-14 上海贺普药业股份有限公司 贺普拉肽的制剂
CN104274827B (zh) * 2013-07-01 2020-07-14 上海贺普药业股份有限公司 贺普拉肽的制剂
CN113171447A (zh) * 2014-08-20 2021-07-27 博尔托拉制药公司 Xa因子解毒剂的冻干制剂
CN113171447B (zh) * 2014-08-20 2024-05-17 博尔托拉制药公司 Xa因子解毒剂的冻干制剂
CN112203698A (zh) * 2018-03-26 2021-01-08 通用电气医疗集团股份有限公司 制剂及制备方法
CN117186173A (zh) * 2023-09-14 2023-12-08 海南大学 抑制Aβ42聚集并降低其细胞毒作用的三肽化合物
CN117186173B (zh) * 2023-09-14 2024-04-05 海南大学 抑制Aβ42聚集并降低其细胞毒作用的三肽化合物

Also Published As

Publication number Publication date
SI2018183T1 (sl) 2017-01-31
EA200802170A1 (ru) 2009-06-30
EP2594284A1 (en) 2013-05-22
KR20090005204A (ko) 2009-01-12
PH12014502880A1 (en) 2016-01-18
MA30474B1 (fr) 2009-06-01
MY162816A (en) 2017-07-31
IL194653A (en) 2016-10-31
JP5873854B2 (ja) 2016-03-01
BRPI0710508B1 (pt) 2018-10-23
CY1118038T1 (el) 2017-05-17
TNSN08391A1 (en) 2010-04-14
JP6787953B2 (ja) 2020-11-18
KR101236042B1 (ko) 2013-02-21
US9283260B2 (en) 2016-03-15
UY30302A1 (es) 2007-10-31
LT2018183T (lt) 2016-11-25
AR060617A1 (es) 2008-07-02
JO3324B1 (ar) 2019-03-13
KR20120114384A (ko) 2012-10-16
CA2649292A1 (en) 2007-11-01
JP2009534392A (ja) 2009-09-24
EP2594285B1 (en) 2016-08-10
ZA200808485B (en) 2009-08-26
CA2649292C (en) 2017-01-17
US10166189B2 (en) 2019-01-01
UA99815C2 (ru) 2012-10-10
MX2008013393A (es) 2009-03-06
NO344947B1 (no) 2020-07-27
DK2018183T3 (en) 2016-11-28
EA201270625A1 (ru) 2012-12-28
AU2007240656A1 (en) 2007-11-01
PL2018183T3 (pl) 2017-04-28
BRPI0710508B8 (pt) 2021-05-25
KR101227278B1 (ko) 2013-01-28
HRP20161653T1 (hr) 2017-01-13
PT2018183T (pt) 2016-12-02
NZ596367A (en) 2013-09-27
TWI352598B (en) 2011-11-21
TW200744624A (en) 2007-12-16
US20160143852A1 (en) 2016-05-26
HUE032144T2 (en) 2017-08-28
EP2594287A1 (en) 2013-05-22
JP2016065060A (ja) 2016-04-28
EP2018183A2 (en) 2009-01-28
PE20081196A1 (es) 2008-09-04
CR20140274A (es) 2014-07-18
JP2021006525A (ja) 2021-01-21
IL224966A (en) 2017-10-31
JP2014040441A (ja) 2014-03-06
WO2007124090A2 (en) 2007-11-01
EA017085B1 (ru) 2012-09-28
UA116080C2 (uk) 2018-02-12
EP2594285A1 (en) 2013-05-22
JP6356106B2 (ja) 2018-07-11
JP2022166219A (ja) 2022-11-01
WO2007124090A3 (en) 2008-12-11
CR10442A (es) 2009-02-19
JP5432705B2 (ja) 2014-03-05
JP2018150380A (ja) 2018-09-27
NO20084893L (no) 2009-01-20
BRPI0710508A2 (pt) 2012-10-30
SG182887A1 (en) 2012-08-30
ES2599318T3 (es) 2017-02-01
EA022424B1 (ru) 2015-12-30
RS55428B1 (sr) 2017-04-28
SG10201501296SA (en) 2015-04-29
US20090258017A1 (en) 2009-10-15
CN107789325A (zh) 2018-03-13
EP2018183B1 (en) 2016-09-07
EP2594288A1 (en) 2013-05-22
CR20170130A (es) 2017-06-15
GEP20156253B (en) 2015-03-10
IL194653A0 (en) 2011-08-01
EP2594286A1 (en) 2013-05-22
IL248156B (en) 2018-07-31

Similar Documents

Publication Publication Date Title
JP2022166219A (ja) 凍結乾燥された治療用ペプチボディ製剤
KR100753304B1 (ko) 치료제로서 사용되는 변이 펩티드를 함유한 화합물로이루어진 조성물 및 이 화합물의 제조방법
US8143380B2 (en) Therapeutic peptides
ES2307539T3 (es) Procedimiento para la correccion de una falta de enlaces disulfuro en moleculas fc.
AU2011265555B2 (en) Lyophilized therapeutic peptibody formulations
HK1128873B (en) Lyophilized therapeutic peptibody formulations
RU2847096C1 (ru) Жидкая композиция конъюгата GLP-2 длительного действия
AU2005265319A1 (en) Therapeutic peptides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20090715

RJ01 Rejection of invention patent application after publication